0211 Quell
BioCentury & Getty Images

Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

Emerging Company Profile: Syncona’s Quell is developing more targeted Treg cell therapies

Backed by Syncona, London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies.

Feb 12, 2021 | 1:18 AM GMT

Read the full 593 word article

How to gain access

Continue reading with a
two-week free trial.